Ocular manifestation of systemic diseases II
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2022.178543Keywords:
Hypertensive retinopathy, hypertension, diabetic retinopathy, diabetes, retina, vascular diseasesAbstract
Given the increase in life expectancy and changes in modern habits and lifestyles, vascular pathologies of the retina, such as hypertensive and diabetic retinopathy, stand out as important causes of visual impairment.
Arterial hypertension can directly cause damage to the retina, choroid and optic nerve, in addition to predisposing to the occurrence of other vascular pathologies, such as retinal venous occlusions, and the worsening of pathologies such as diabetic retinopathy. Diabetes mellitus can lead to multiple ophthalmic complications, with retinopathy being the most prevalent and figuring as the main cause of blindness in the economically active population.
In this scenario, both general physicians and diverse specialists must be aware of the risk of ophthalmological impairment and perform appropriate management of the underlying pathology, early recognition of eye changes and timely referral to specialized services, in order to avoid visual, economic and social impairment. often associated with these pathologies.
Downloads
References
Alves MR, Avila M, Lavinsky J, Moreira Junior CA, editors. Retina e vítreo / Conselho Brasileiro de Oftalmologia . 4.ed. Rio de Janeiro: Cultura Médica; 2016.
Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–88. https://doi.org/10.1016/S0140-6736(18)32203-7
Oliveira JEP de, Montengro Junior RM, Vencio S, editors. Diretrizes da Sociedade Brasileira de Diabetes 2017-2018. São Paulo: Editora Clannad; 2017.
Leasher JL, Bourne RRA, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al. Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010. Diabetes Care. 2016;39:1643–9. https://doi.org/10.2337/dc15-2171
McCannel CA, Berrocal AM, Holder GE, Kim SJ, Leonard BC, Rosen RB, et al., editors. Retina and Vitreous / Basic and Clinical Science Course 2019-2020. San Francisco: American Academy of Ophthalmology; 2019.
Gross JL, Nehme M. Detecção e tratamento das complicações crônicas do diabetes melito: Consenso da Sociedade Brasileira de Diabetes e Conselho Brasileiro de Oftalmologia. Rev Assoc Med Bras. 1999;45:279–84. https://doi.org/10.1590/S0104-42301999000300014
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Diabetic Retinopathy Preferred Practice Pattern®. Ophthalmology. 2020;127:P66–145. https://doi.org/10.1016/j.ophtha.2019.09.025
Klein R. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Ophthalmol. 1984;102:520. https://doi.org/10.1001/archopht.1984.01040030398010
Sayin N. Ocular complications of diabetes mellitus. World J Diabetes. 2015;6:92. https://doi.org/10.4239/wjd.v6.i1.92
Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global Prevalence and Major Risk Factors of Diabetic Retinopathy. Diabetes Care. 2012;35:556–64. https://doi.org/10.2337/dc11-1909
Corrêa ZM da S, Eagle Jr R. Aspectos patológicos da retinopatia diabética. Arq Bras Oftalmol. 2005;68:410–4. https://doi.org/10.1590/S0004-27492005000300028
Focal Photocoagulation Treatment of Diabetic Macular Edema. Arch Ophthalmol. 1995;113:1144. https://doi.org/10.1001/archopht.1995.01100090070025
Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–82. https://doi.org/10.1016/S0161-6420(03)00475-5
Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials. Ophthalmology. 2013;120:2013–22. https://doi.org/10.1016/j.ophtha.2013.02.034
Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL, Friedman SM, et al. Expanded 2-Year Follow-up of Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema. Ophthalmology. 2011;118:609–14 https://doi.org/10.1016/j.ophtha.2010.12.033.
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015;372:1193–203. https://doi.org/10.1056/NEJMoa1414264
Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL, et al. Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment. Ophthalmology. 2012;119:2312–8. https://doi.org/10.1016/j.ophtha.2012.08.022.
Malachias MVB et al. 7a Diretriz Brasileira de Hipertensão Arterial. Arq Bras Cardiol. 2016;107:1–104.
Grosso A. Hypertensive retinopathy revisited: some answers, more questions. Br J Ophthalmol. 2005;89:1646–54. https://doi.org/10.1136/bjo.2005.072546
Wong T, Mitchell P. The eye in hypertension. Lancet. 2007;369:425–35. https://doi.org/10.1016/S0140-6736(07)60198-6
Wong TY, Mitchell P. Hypertensive Retinopathy. N Engl J Med. 2004;351:2310–7. https://doi.org/10.1056/NEJMra032865.
Jacomini CZ, Hannouche RZ. Retinopatia hipertensiva. Rev bras hipertens. 2001;8:321–7
Tso MOM, Jampol LM. Pathophysiology of Hypertensive Retinopathy. Ophthalmology. 1982;89:1132–45. https://doi.org/10.1016/S0161-6420(82)34663-1
Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci. 1974;268:336–45. https://doi.org/10.1097/00000441-197412000-00004
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Thaís Marino de Azeredo Bastos, Ítalo Pena de Oliveira, Rodrigo Jorge
This work is licensed under a Creative Commons Attribution 4.0 International License.
